Today on 14 April 2016, an extraordinary shareholders' meeting was held in Enzymatica AB (publ) ("Enzymatica" or the "Company"). The meeting decided on a rights issue with pre-emptive right for the shareholders with expected proceeds of approximately SEK 60 million before issue costs. In addition the meeting decided to authorise the board of directors until the next annual shareholders' meeting to increase the Company's share capital by a directed share issue of no more than 17,500,000 new shares. A summary of the resolutions adopted follows below. All resolutions were adopted unanimously.
Amendment to the articles of association
The meeting resolved in accordance with the proposal of the board of directors to amend the articles of association as follows.
|Previous wording||Adopted wording|
|§ 4||The share capital shall be no less than SEK 500,000 and no more than SEK 2,000,000.|| The share capital shall be no less than SEK |
1,500,000 and no more than SEK 6,000,000.
|§ 5||The number of shares in the Company shall not be lower than 12,500,000 and not higher than 50,000,000.||The number of shares in the Company shall not be lower than 37,500,000 and not higher than 150,000,000.|
Rights issue with pre-emptive right for the shareholders
The meeting resolved in accordance with the proposal of the board of directors on a rights issue with expected proceeds of approximately SEK 60 million before issue costs. Through the rights issue, the Company's share capital can be increased with a maximum amount of SEK 1,100,817.12 divided into a maximum of 27,520,428 shares. The main terms and conditions for the rights issue are as following.
The Company's shareholders shall have pre-emptive right to subscribe for new shares in proportion to the shares previously owned. Each previously owned share confers the right to one (1) subscription right. Five (5) subscription rights entitles subscription for three (3) new shares. The subscription price to be paid shall be SEK 2.18 for each new share.
The record date for entitlement to participate in the rights issue with pre-emptive right shall be 19 April 2016. Subscription for new shares shall be made during the time period as from 21 April 2016 - 6 May 2016. Subscription by exercise of subscription rights shall be made by simultaneous cash payment. Subscription for new shares without subscription rights shall be made on a separate subscription list. Payment for new shares subscribed for without subscription rights shall be made in cash no later than the third bank day from dispatch of the contract note setting forth the allotment of shares to the subscriber. The board of directors shall be entitled to extend the period for subscription and payment.
Authorisation of the board of directors to issue new shares
The meeting resolved in accordance with the proposal of the board of directors to authorise the board of directors until the next annual shareholders' meeting to, on one or more occasions, resolve to increase the Company's share capital by issue of no more than 17,500,000 new shares. The board of directors may deviate from the shareholders' preferential rights. The reason for the board of directors' authorisation to deviate from the shareholders' preferential rights is to enable the company's possibilities to raise new capital and to take advantage of future opportunities to attract new long-term owners of strategic importance to the company, as well as to finance the Company's growth strategy. The authorization also includes the right to decide on payment for the issued shares in kind, set-off or other conditions as referred in Chap. 13 Sec. 5 item 6 of the Swedish Companies Act (Sw. Aktiebolagslagen (2005:551)). At a deviation from the shareholders' preferential rights, the issue rate shall be determined in accordance with market conditions.
For more information, please contact:
Fredrik Lindberg, CEO Enzymatica AB
Tel: +46 708-86 53 70 | E-post: firstname.lastname@example.org
About Enzymatica AB
Enzymatica is a life science company who develops and sells medical device products against infectious-related diseases. Over a short period the company has developed a unique oral spray for colds, ColdZyme®, and launched it on six markets. The product has become one of the leading articles for colds in Swedish pharmacies. Enzymatica's strategy is to continue growing by strengthening its position in existing markets and to expand to more geographical markets through well-established partners. The company is headquartered in Lund, Sweden and is listed on Nasdaq First North. For more information, please visit www.enzymatica.com.
Enzymatica's certified advisor is Erik Penser Bankaktiebolag.